Genetron Health Joins Major R&D Project Led by the Ministry of Science and Technology in China for Early Screening of Lung and Digestive System Cancers

Written by Customer Service on August 29, 2020. Posted in Public Companies.

BEIJING, Aug. 29, 2020 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, today announced its participation in the launch of a major national research project for early screening of lung and digestive system cancers led by China’s Ministry of Science and Technology (“MOST”).Based on the Company’s proprietary technology, Mutation CapsuleTM, Genetron Health is collaborating with the National Cancer Center and the Cancer Hospital, Chinese Academy of Medical Sciences (“CAMS”) for the second time, to provide key technological contributions for the “Liquid Biopsy-based Malignant Tumor Early Screening Technology Research and Development Project”. The launch meeting for the project...

MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Written by Customer Service on August 29, 2020. Posted in Public Companies.

EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The LancetPresentation Expands on Positive Topline Results Showing Early, Sustained Reductions in Biomarkers of Cardiac Wall Stress and Myocardial InjuryMavacamten Demonstrated Broad Treatment Effect, with Consistent Benefit Across Primary and Secondary Endpoints Among All Prespecified Patient SubgroupsMyoKardia to Host a Virtual Analyst and Investor Event toReview Data on Monday, August 31 at 8:00 a.m. EDTBRISBANE, Calif., Aug. 29, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) announced today that 30-week results from its pivotal Phase 3 EXPLORER-HCM clinical trial of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM) were presented during a live Hot Line session at the...

Medtronic Cryoablation Superior to Drug Therapy for Symptomatic Paroxysmal Atrial Fibrillation

Written by Customer Service on August 29, 2020. Posted in Public Companies.

ESC Congress: New Research Highlights First-Line Use of Cryoablation as Highly Effective, and with Improved Quality of Life ScoresDUBLIN, Aug. 29, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced clinical trial results demonstrating superiority of the Arctic Front™ Advance Cardiac Cryoballoon and Freezor® MAX Cardiac CryoAblation Catheter for the first-line treatment (prior to drug therapy) of recurrent symptomatic paroxysmal atrial fibrillation (PAF) compared to antiarrhythmic drug (AAD) treatment. Primary results of the randomized STOP AF First trial were presented as a late breaking clinical trial at the European Society of Cardiology (ESC) Congress 2020 Digital Experience. Additionally, 12-month outcomes from the Cryo-FIRST trial showed a significant improvement in atrial...

LexinFintech Wins The Asian Banker Award for Best AI and Innovation Lab in China

Written by Customer Service on August 29, 2020. Posted in Public Companies.

SHENZHEN, China, Aug. 29, 2020 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin”) (NASDAQ: LX), a leading online consumption and consumer finance platform for educated young professionals in China, has been awarded the Best AI and Innovation Lab Award in China by The Asian Banker, whose awards are seen as an undisputed benchmark measuring the performance of the best banks and fintech companies in Asia.“Lexin’s AI Lab significantly enhanced the company’s operating efficiency and increased its profitability by providing automated artificial intelligence services throughout every step of its transaction processes. Both of its research and development (R&D) expense and R&D personnel as a percentage of total employee headcount have been maintained at levels that lead the industry,” The Asian Banker commented.A...

NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study

Written by Customer Service on August 29, 2020. Posted in Public Companies.

Late-breaker presentation selected as “Best of ILC”The 24-week Phase 2 study met its primary endpoint, achieving a statistically significant reduction in liver fat content (LFC), and robust fibrosis improvement and resolution of NASH, with a favorable safety profileNew analysis shows 30% placebo corrected anti-fibrotic response rate among NASH patients with more advanced liver fibrosis (F3)NGM Bio anticipates Phase 2b ALPINE 2/3 study topline data readout in Q2 2021SOUTH SAN FRANCISCO, Calif., Aug. 29, 2020 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that final data from its 24-week Phase 2 study (Cohort 4) of aldafermin 1 mg in patients with non-alcoholic steatohepatitis (NASH) were featured...

Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)

Written by Customer Service on August 29, 2020. Posted in Public Companies.

New data will be presented in an e-poster today at the Virtual Edition of the 46th EBMT Annual MeetingAmsterdam, The Netherlands, August 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell-based medicines for the treatment of life-threatening diseases, today announces that new data supporting the Company’s NK cell therapy is being presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). The poster presents data from 13 patients treated with relapsed/refractory acute myeloid leukemia (R/R AML) who received treatment with FC21 expanded NK-cells during a Phase I study conducted by Lucia Mariano da Rocha Silla, MD, PhD, at Hospital de Clínicas de Porto Alegre (HCPA) in Brazil....

Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Written by Customer Service on August 29, 2020. Posted in Public Companies.

Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumabSeven of ten patients discontinued eculizumab and remained on LNP023 as monotherapy, retaining hemoglobin (Hb) levels with no changes in biomarkers of disease activity and with no signs or symptoms of breakthrough hemolysis Phase II results are promising for treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder;1,2 second Phase II study with LNP023 monotherapy in anti-C5 naïve PNH patients ongoing First-in-class LNP023 – which potently and selectively targets factor B, part of the immune system’s alternative complement pathway3,4,5 – is also in development for several renal conditions with complement system involvement FDA and EMA have granted orphan drug...

VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020

Written by Customer Service on August 29, 2020. Posted in Public Companies.

Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPASignificant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides further insight to potential mechanisms of actionVASCEPA is the first and only agent studied on top of statins reported to exhibit coronary plaque regression in hypertriglyceridemic patientsDUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 29, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that the trial results from Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: Final results of the EVAPORATE Trial were presented at ESC Congress 2020, the annual meeting of the European Society of Cardiology, on August 29, 2020, 9:13 am CEST (Central...

Synergy Capital AM: Stocks ended up mixed but S&P 500 kept its pace hitting another fresh new high

Written by Customer Service on August 29, 2020. Posted in Public Companies.

Major indices closed down market mixed after concerns about Federal Reserve’s reports on a new framework that could keep interest rates lower for a longer period of time gave investors not much of positivity.Nasdaq fell quite big after tech giants dropped. Amazon is down with 1.2% while Facebook slid 2.3%. Netflix also decreased about 3.9% but Alphabet made a few jump at 1%.Here are the main movements in the Global Stock Market;Stocks– Nasdaq Composite snaps out of its passive pace and fell short losing around 39.72 points or 0.34% to 11,625.34.– S&P 500 hits another fresh new high for the 4th time this week with 5.84 points or 0.17% increased to 3,484.57 as market ends today.– The Dow Jones Industrial Average jumps up with 160.15 or 0.57% change to 28,492.07, deleting some of its loss from yesterday.– The...

Company Announcement 08/2020

Written by Customer Service on August 29, 2020. Posted in Public Companies.

August 29, 2020NORDIC SHIPHOLDING A/S Company Announcement: 08/2020H1 Result 2020SummaryThe comparison figures for period ended 30 June 2019 are stated in parenthesis.The very high Time Charter Equivalent (“TCE”) rates arising from the short-term surge in demand for tonnage caused by the COVID-19 pandemic and the oil price war which started in Q1 2020 positively impacted the Group’s earnings in H1 2020. As a result, the average daily TCE rate earned in H1 2020 by the 5 vessels was approximately 20% and 83% higher than the average TCE rate earned in Q4 2019 and H1 2019, respectively.For the 6 months ended 30 June 2020, the Group generated a profit after tax ofUSD 5.7 million (loss of USD 1.3 million) primarily due to improved TCE revenue generated.Despite the sale of Nordic Ruth in July 2019, TCE revenue rose 59.8% to USD 19.4 million...

Day: August 29, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice